ValGenesis Inc. Secures $24 Million Investment from Morgan Stanley Expansion Capital
May 04 2021 - 10:00AM
Business Wire
ValGenesis, Inc. (“ValGenesis”), the market leader in Enterprise
Validation Lifecycle Management Systems (VLMS), announced the
closing of a $24 million investment from Morgan Stanley Expansion
Capital. Proceeds will bolster sales and accelerate ValGenesis’
focus on innovation in digital validation technologies and global
deployment.
ValGenesis is the inventor and first-mover to digitize the
validation lifecycle process. ValGenesis VLMS is the industry's
first, proven, 100% end-to-end paperless validation lifecycle
management solution, trusted by global life science organizations
as a system of record for validation. Covering the entire
validation lifecycle process, ValGenesis VLMS delivers technology
solutions that are validated, fully configurable, and rapidly
deployable through a private secured Cloud.
"The world of digitalization has emerged so strongly that today
it is an inescapable part of life broadly and specifically in the
life science industry. Technologies such as artificial intelligence
(AI), the internet of things (IoT), and augmented reality (AR) are
essential for supporting remote process management, including
validation in the life science industry. ValGenesis is at the
cutting edge of digital validation technology and is trusted by
over 30 of the top 50 global life science companies. We are
thrilled to secure this funding from Morgan Stanley Expansion
Capital; it will help us aggressively pursue our vision of becoming
the de facto standard for digital validation lifecycle management,"
says Dr. Siva Samy, CEO & Chief Product Strategist of
ValGenesis, Inc.
“Digitization of backend processes and workflow automation is a
rapidly emerging area of growth for healthcare and life sciences
companies. As a market leader, ValGenesis offers a fit-for-purpose
platform for validation lifecycle management, resulting in
significant cost and time efficiencies for global, compliance
focused organizations,” said Melissa Daniels, Managing Director,
Morgan Stanley Expansion Capital. “We believe ValGenesis’ VLMS
offers a compelling value proposition, and are excited to partner
with Dr. Samy, a visionary in the VLMS market, to support the
company as it continues on its growth trajectory.”
The funding builds on a successful 2020 during which ValGenesis
augmented its VLMS to leverage new, cutting-edge digital validation
technologies, helping ValGenesis build up a large customer base
across the globe. With the latest round of investment, ValGenesis
will continue to focus on driving innovative validation technology
solutions that solve today's most significant challenges in the
life science industry.
About ValGenesis
ValGenesis, Inc. is the creator of an innovative software
platform that serves as a foundation for managing compliance-based
validation activities in life science companies. ValGenesis, Inc.
is the provider of the first enterprise application for efficient
management of corporate validation lifecycle processes. This
solution is fully compliant with U.S. FDA 21 CFR Part 11 and Annex
11 requirements. As the first fully paperless solution for
electronic management of validation execution and approval,
ValGenesis was selected by an industry peer review committee to
receive the Parenteral Drug Association (PDA) New Innovative
Technology Award in 2005.
For more information, visit www.valgenesis.com.
About Morgan Stanley Expansion Capital
Morgan Stanley Expansion Capital is the growth-focused private
investment platform within Morgan Stanley Investment Management.
Morgan Stanley Expansion Capital targets growth equity and credit
investments within technology, healthcare, consumer, digital media,
and other high-growth sectors. For over three decades, Morgan
Stanley Expansion Capital has successfully pursued growth
investment opportunities and has completed investments in over 200
companies leveraging the global brand and network of Morgan
Stanley. For further information about Morgan Stanley Expansion
Capital, please visit
www.morganstanley.com/im/expansioncapital.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210504005974/en/
ValGenesis Communications Media Contact: Althea D'Sylva
+1 510-445-0505 Ex.1026 althea.dsylva@valgenesis.com
Morgan Stanley (NYSE:MS)
Historical Stock Chart
From Apr 2024 to May 2024
Morgan Stanley (NYSE:MS)
Historical Stock Chart
From May 2023 to May 2024